Home   /  Find a Trial  /  See All TrialsHELP /  AYUDA /  求助 : (415) 476-5777 | Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Treatment:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

Advanced/Metastatic Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

Sites with evidence of disease:

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
Young Survivors

Genetic Testing Decisions In Newly Diagnosed Ashkenazi Women

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer (NCT01386411)

Summary

Women who are diagnosed with breast cancer at a young age and/or who are of Ashkenazi Jewish descent are more likely to carry the BRCA1 or BRCA2 genetic mutation that increases risk for breast and ovarian cancer. Genetic testing for the BRCA1/2 mutation can help women make decisions about their breast cancer treatment. The purpose of this trial is to see whether women prefer having genetic testing before or after their breast cancer surgery. The study will also look at how women feel about their decision at a later date. To be eligible for this trial, participants must be 18 – 50 years old at diagnosis, be of Ashkenazi Jewish descent, and be planning to undergo breast surgery as part of their treatment.

Breast Cancer in Young Women

Identification of Novel Genetic Risk Factors That Contribute to the Risk for Breast Cancer (NCT00276120)

Summary

Breast cancer is the leading cause of cancer deaths in women 20-39 years of age. The goal of this trial is to identify the genetic factors that distinguish breast cancer in younger women compared to older women. The researchers hope that identifying these genetic factors will lead to new treatments for younger women who have been diagnosed with breast cancer or who are at high-risk for developing the disease. All women who were diagnosed with breast cancer at age 40 or younger (regardless of current age) are eligible to participate. Because all study-related materials will be mailed, participants can live anywhere in the U.S.

  • Participation TimeBlood sample and questionnaire by mail
  • No Visits Required for this TrialNo travel required 

Sexual and Reproductive Health Study

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma (NCT01788839)

Summary

Cancer and its treatment may affect sexual and reproductive health. To help researchers learn more about the problems women face, participants in this study will complete questionnaires on sexuality and pregnancy before, during, and after cancer treatment. The information will be used to help doctors identify which women are most likely to have early menopause or develop sexual problems during cancer therapy, or have difficulty getting pregnant after cancer treatment. To be eligible for this study a woman must be age 50 or younger, newly diagnosed with breast cancer, and planning on having, or within one month of starting, chemotherapy.

The Young Women's Breast Cancer Study

Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study (NCT01468246)

Summary

Young women with breast cancer have unique needs and concerns. The goal of this study is to follow a large group of young women with breast cancer over time to learn more about the types of tumors they develop, the treatments they have, the side effects they experience, and the psychosocial concerns they face. The researchers are also interested in seeing if there is a relationship between tumor biology and patient outcome. To be eligible, participants must have been diagnosed with breast cancer at age 40 or younger.

Measuring Breast Density in Premenopausal Breast Cancer Patients on Tamoxifen

Development of a Quantitative Tissue Optical Index of Breast Density (NCT01773551)

Summary

Some studies have suggested that premenopausal breast cancer patients whose breasts become less dense (as measured by a mammogram) while they are on tamoxifen are less likely to have a recurrence than women on tamoxifen whose breast density does not change. Researchers have developed a new tool called diffuse optical spectroscopic imaging that uses light to measure tissue thickness. This study is looking at whether this new tool can be used to measure changes in breast density. To be eligible, a woman must be premenopausal and taking tamoxifen to treat stage I - III breast cancer.

Ovarian Function After DCIS and Breast Cancer

Predictors of Ovarian Insufficiency Through Serial Exams in Young Breast Cancer Patients (POISE Study) (NCT01197456)

Summary

Premenopausal women may face issues related to having children as they undergo breast cancer care, and these concerns may influence their treatment choices. Tools that can accurately predict how treatment may affect ovarian function could help women and their doctors make choices that take into account the potential impact on fertility. The goal of this study is to identify pre-chemotherapy hormonal, genetic, and ovarian imaging markers that can predict whether a woman's ovaries are likely to continue to function at the end of her cancer treatments. Participants will be followed from the time of diagnosis to five years after treatment.

Immune System Response to Breast Cancer in Women Under Age 50

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction (NCT01503190)

Summary

Researchers are interested in learning more about the role the immune system plays in cancer. This study is looking specifically at the immune system in women with breast cancer who are under age 50. The researchers will look to see if differences in their immune system correspond to different types of tumors including tumors that develop during or after a pregnancy. The investigators may go on to use some of the breast cancer tissue collected in this study to create models that could be used to develop and test new drug treatments.